22048-71-1

Usage

Uses

Used in Pharmaceutical Synthesis:
[4-(1H-pyrrol-1-yl)phenyl]acetic acid is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its presence in the molecular structure of certain drugs contributes to their therapeutic effects, making it an essential component in drug development.
Used in Organic Chemistry:
In the field of organic chemistry, [4-(1H-pyrrol-1-yl)phenyl]acetic acid serves as a versatile building block for the creation of complex organic compounds. Its reactivity and structural features facilitate the synthesis of a wide range of organic molecules, broadening its applications in research and industrial processes.
Used in Medicinal Chemistry:
[4-(1H-pyrrol-1-yl)phenyl]acetic acid is employed in medicinal chemistry for its potential to enhance the biological activity of compounds. The pyrrole ring in its structure can interact with biological targets, potentially leading to the development of new drugs with improved efficacy and selectivity.
Overall, [4-(1H-pyrrol-1-yl)phenyl]acetic acid is a multifaceted chemical compound with applications spanning across pharmaceuticals, organic chemistry, and medicinal chemistry, highlighting its importance in scientific research and industrial applications.

InChI:InChI=1/C12H11NO2/c14-12(15)9-10-3-5-11(6-4-10)13-7-1-2-8-13/h1-8H,9H2,(H,14,15)

Upstream product

• 696-59-3 cis,trans-2,5-dimethoxytetrahydrofuran 
• 1197-55-3 4-aminophenylacetic acid 
• 827-60-1 1-(4-methylphenyl)-1H-pyrrole 
• 124-38-9 carbon dioxide 

Downstream Products

• 93372-02-2 1-[2-(4-Pyrrol-1-yl-phenyl)-ethyl]-piperidine 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41

On the basis of the structures of small-molecule hits targeting the HIV-1 gp41, N-(4-carboxy-3-hydroxy)phenyl-2,5-dimethylpyrrole (2, NB-2), and N-(3-carboxy-4-chloro)phenylpyrrole (A1, NB-64), 42 N-carboxyphenylpyrrole derivatives in two categories (A and B series) were designed and synthesized. We found that 11 compounds exhibited promising anti-HIV-1 activity at micromolar level and their antiviral activity was correlated with their inhibitory activity on gp41 six-helix bundle formation, suggesting that these compounds block HIV fusion and entry by disrupting gp41 core formation. The structure-activity relationship and molecular docking analysis revealed that the carboxyl group could interact with either Arg579 or Lys574 to form salt bridges and two methyl groups on the pyrrole ring were favorable for interaction with the residues in gp41 pocket. The most active compound, N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrrole (A12), partially occupied the deep hydrophobic pocket, suggesting that enlarging the molecular size of A12 could improve its binding affinity and anti-HIV-1 activity for further development as a small-molecule HIV fusion and entry inhibitor.

Efficient methods for optional metalation of 1-(methylphenyl)pyrroles in α or benzylic positions

Novel, selective metalation methods have been described for optional functionalisation of 1-(methylphenyl)pyrroles in α or benzylic positions and an efficient way for dilithiation of the model compounds has also been reported.